Chronic active disease pattern predicts early damage in juvenile systemic lupus erythematosus

Lupus

Volumn 24, Issue 13, 2015, Pages 1421-1428

  Sato, J O ^a   Corrente, J E ^a   Saad Magalhaes C ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Childhood onset systemic lupus erythematosus; damage; disease activity patterns; juvenile systemic lupus erythematosus; outcomes research

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID;

ADOLESCENT; ALOPECIA; ARTICLE; ASSESSMENT OF HUMANS; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; GROWTH DISORDER; HUMAN; JUVENILE; JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS; KIDNEY FAILURE; MALE; PEDIATRIC SLICC ACR DAMAGE INDEX; PRIORITY JOURNAL; SLEDAI; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

ADOLESCENT; ALOPECIA; CHILD; CHRONIC DISEASE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 84945243809     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315599449     Document Type: Article

References (37)

1. Silverman E, Eddy A, Systemic lupus erythematosus. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, (eds). Textbook of pediatric rheumatology, 6th ed. Philadelphia: Elsevier Saunders, 2011, pp. 315-343.
2. Barr SG, Zonana-Nacach A, Magder LS, Petri M,. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 12: 2682-2688.
3. Zen M, Bassi N, Nalotto L, et al. Disease activity patterns in a monocentric cohort of SLE patients: A seven-year follow-up study. Clin Exp Rheumatol 2012; 30: 856-863.
4. Otten MH, Cransberg K, van Rossum MA, et al. Disease activity patterns in juvenile systemic lupus erythematosus and its relation to early aggressive treatment. Lupus 2010; 19: 1550-1556.
5. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,. Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
6. Gladman DD, Ibañez D, Urowitz MB,. Systemic lupus erythematosus disease activity index 2000. J Rheumatology 2002; 29: 288-291.
7. Uribe AG, Vilá LM, McGwin G Jr, Sanchez ML, Reveille JD, AlarcÏn GS,. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004; 31: 1934-1940.
8. Brunner HI, Feldman BM, Bombardier C, Silverman ED,. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1354-1360.
9. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the SLICC/ACR damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
10. Gutiérrez-Suárez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2989-2996.
11. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19: 949-956.
12. Laustrup H, Voss A, Green A, Junker P,. SLE disease patterns in a Danish population-based lupus cohort: An 8-year prospective study. Lupus 2010; 19: 239-246.
13. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
14. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 541-547.
15. Bencivelli W, Vitali C, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 549-554.
16. Brunner HI, Silverman ED, Bombardier C, Feldman BM,. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2003; 49: 335-341.
17. FitzGerald JD, Grossman JM,. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 1999; 8: 638-644.
18. Mosca M, Bencivelli W, Vitali C, et al. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000; 9: 445-450.
19. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000; 314: 1-27.
20. Landis JR, Koch GG,. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
21. Steiman AJ, Urowitz MB, Ibañez D, Papneja A, Gladman DD,. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014; 41: 1808-1816.
22. Gómez-Puerta JA, Pons-Estel BA, Cervera R,. Prolonged remission in SLE revisited: An old wine in a new bottle. J Rheumatol 2014; 41: 1728-1731.
23. Ravelli A, Ruperto N, Martini A,. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17: 568-573.
24. Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2012; 64: 2356-2365.
25. Dung NT, Loan HT, Nielsen S, Zak M, Petersen FK,. Juvenile systemic lupus erythematosus onset patterns in Vietnamese children: A descriptive study of 45 children. Pediatr Rheumatol Online J 2012; 10: 38-38.
26. Ravelli A, Duarte-Salazar C, Buratti S, et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis Rheum 2003; 49: 501-507.
27. Bandeira M, Buratti S, Bartoli M, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006; 15: 515-520.
28. Rygg M, Pistorio A, Ravelli A, et al. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis 2012; 71: 511-517.
29. Becker-Merok A, Nossent HC,. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006; 33: 1570-1577.
30. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM,. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-444.
31. Ziakas PD, Dafni UG, Giannouli S, Tzioufas AG, Voulgarelis M,. Thrombocytopaenia in lupus as a marker of adverse outcome-seeking Ariadne's thread. Rheumatology (Oxford) 2006; 45: 1261-1265.
32. Fernández M, Alarcón GS, Apte M, et al. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum 2007; 56: 614-521.
33. Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Carmargo-Coronel A,. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus 2007; 16: 997-1000.
34. Zhao H, Li S, Yang R,. Thrombocytopenia in patients with systemic lupus erythematosus: Significant in the clinical implication and prognosis. Platelets 2010; 21: 380-385.
35. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686.
36. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
37. Lilleby V, Flatø B, Førre O,. Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23: 261-269.